Skip to main content

Heron Therapeutics, Inc 8-K, filed Nov 9, 2026

Heron Therapeutics, Inc. (HRTX)

8-K 2026-11-09 For: 2026-11-09
View Original
Added on November 09, 2026

About this 8-K

Heron Therapeutics, Inc filed this 8-K on November 9, 2026.

Heron Therapeutics and CorMedix Therapeutics entered a definitive agreement for CorMedix to acquire substantially all of its assets, subject to stockholder approval and customary closing conditions. Q3 2026 net revenue was $35.3 million, versus $38.2 million in Q3 2025. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits